-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the world's leading biotechnology company GenScript (stock code: 1548.
GenScript's cPass SARS-CoV-2 neutralizing antibody test kit is widely used in 24 regions throughout the Middle East and North Africa to evaluate the effectiveness of the new coronary pneumonia vaccine.
This serum kit called cPass sVNT Kit is the world’s first kit that can quickly and effectively detect functional neutralizing antibodies developed by Duke-National University of Singapore School of Medicine.
It is reported that neutralizing antibodies can inhibit virus infection and spread by preventing the virus from binding to specific receptors of host cells, and become the first line of defense against SARS CoV-2 infection.
Since its launch, cPass sVNT Kit has been highly regarded in the international market for its advantages of simplicity, speed, convenience and effectiveness.
It is reported that in February 2021, GenScript has reached a cooperation agreement with Nine Strong Biotech and Sinopharm Investment (a member company of Sinopharm Group) on the promotion of its commercial application in China, in order to better utilize the advantages of all parties and make this efficient Testing services will be promoted to the front line as soon as possible, benefiting more people, and contributing to China's anti-epidemic cause.
Dr.
Johnson Wang, President of GenScript Asia Pacific, said: "We are very pleased to cooperate with G42 Healthcare to provide innovative solutions to help people in the UAE and more regions.
Leave a message here
